Novo Nordisk ® ab reduced the number of bleeds nhibitors Key highlights Efficacy • Median ABR was 0 for concizumab prophylaxis treatment, compared to 9.8 in the on-demand treatment group • Estimated mean ABR was 1.7 for concizumab prophylaxis treatment, compared to 11.8 in the on-demand treatment group • For patients on concizumab prophylaxis, 64% had 0 bleeds in Group 2 Safety • Concizumab appeared to have a safe and well tolerated profile Status • US Complete Response Letter for HwI received in Q2 2023, resubmission end of 2023 expected • JP submission for HwI completed in Q3 2022 • Explorer8 in non-inhibitor patients was completed in Q3 2022 a with inhibitors; OnD: On-demand; PPX: Prophylaxis; ABR annualised bleeding rate
Download PDF file